After going head-to-head with Prevnar 20, Vaxcyte's 24-valent pneumococcal shot will seek a pivotal win

Vaxcyte, a Bay Area company with fewer than 100 employees, touted Phase I/II data from its 24-valent vaccine Monday morning showing the shot was just as safe as Pfizer’s recently approved Prevnar 20 — a 20-valent vaccine. On top of that, Vaxcyte’s shot, dubbed VAX-24, induced greater immune responses in 16 of the 20 valents it shares with Pfizer’s vaccine.